

● NATIONAL FUNDING/ACCESS DECISIONS

NICE decisions

- ▶ **Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (April 2006)** NICE TA100
Capecitabine alone or oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes' C) colon cancer.
www.nice.org.uk/TA100
- ▶ **Irinotecan, oxaliplatin, and raltitrexed for advanced colorectal cancer (August 2005)** NICE TA93
A combination of fluorouracil and folinic acid with either irinotecan or oxaliplatin are options for first-line treatment for advanced colorectal cancer.
Irinotecan alone or fluorouracil and folinic acid with oxaliplatin are options for patients who require further treatment subsequently.
www.nice.org.uk/TA93

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

▶ Oxaliplatin (Non-proprietary)

Oxaliplatin 5 mg per 1 ml Oxaliplatin 50mg/10ml concentrate for solution for infusion vials | 1 vial [PoM] £146.80-£163.78 (Hospital only) | 1 vial [PoM] £155.00

Oxaliplatin 100mg/20ml concentrate for solution for infusion vials | 1 vial [PoM] £289.50-£327.98 (Hospital only) | 1 vial [PoM] £311.00
Oxaliplatin 200mg/40ml concentrate for solution for infusion vials | 1 vial [PoM] £591.26-£655.96 (Hospital only)

ANTINEOPLASTIC DRUGS > PODOPHYLLOTOXIN DERIVATIVES

Etoposide

12-Jul-2018

● INDICATIONS AND DOSE

Small cell carcinoma of the bronchus, the lymphomas and testicular cancer

- ▶ BY MOUTH
Adult: 120–240 mg/m² daily for 5 days
- ▶ BY INTRAVENOUS INFUSION
Adult: (consult product literature)

IMPORTANT SAFETY INFORMATION

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 938.

- **INTERACTIONS** → Appendix 1: etoposide
- **SIDE-EFFECTS**

GENERAL SIDE-EFFECTS

- ▶ **Common or very common** Abdominal pain · acute leukaemia · alopecia · anaemia · appetite decreased · arrhythmia · asthenia · bone marrow depression · constipation · diarrhoea · dizziness · hepatotoxicity · hypertension · leucopenia · malaise · mucositis · myocardial infarction · nausea · neutropenia · skin reactions · thrombocytopenia · vomiting
- ▶ **Uncommon** Nerve disorders
- ▶ **Rare or very rare** Dysphagia · neurotoxicity · radiation recall reaction · respiratory disorders · seizure · severe cutaneous adverse reactions (SCARs) · taste altered · vision loss

SPECIFIC SIDE-EFFECTS

- ▶ **Common or very common**
- ▶ With intravenous use Anaphylactic reaction · hypotension · infection
- ▶ With oral use Oesophagitis · stomatitis · transient systolic hypotension
- ▶ **Uncommon**
- ▶ With intravenous use Haemorrhage

- ▶ **Rare or very rare**
- ▶ With intravenous use Fever
- ▶ With oral use Drowsiness
- ▶ **FREQUENCY NOT KNOWN**
- ▶ With intravenous use Angioedema · extravasation necrosis · infertility · tumour lysis syndrome
- **CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see *Pregnancy and reproductive function* in Cytotoxic drugs p. 938.
- **PREGNANCY** Avoid (teratogenic in *animal studies*). See also *Pregnancy and reproductive function* in Cytotoxic drugs p. 938.
- **BREAST FEEDING** Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution (increased risk of accumulation).
- **RENAL IMPAIRMENT**
Dose adjustments Consider dose reduction—consult local treatment protocol for details.
- **DIRECTIONS FOR ADMINISTRATION** Etoposide may be given orally or by slow intravenous infusion, the oral dose being double the intravenous dose. A preparation containing etoposide phosphate can be given by intravenous injection or infusion. Etoposide is usually given daily for 3–5 days and courses should not be repeated more frequently than at intervals of 21 days.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

▶ Etoposide (Non-proprietary)

Etoposide 20 mg per 1 ml Etoposide 100mg/5ml concentrate for solution for infusion vials | 1 vial [PoM] £11.50-£16.29 (Hospital only)

Etoposide 200mg/10ml concentrate for solution for infusion vials | 1 vial [PoM] £38 (Hospital only)

Etoposide 500mg/25ml concentrate for solution for infusion vials | 1 vial [PoM] £60.70-£81.42 (Hospital only)

Capsule

CAUTIONARY AND ADVISORY LABELS 23

▶ Vepesid (Cheplapharm Arzneimittel GmbH)

Etoposide 50 mg Vepesid 50mg capsules | 20 capsule [PoM] £99.82
Etoposide 100 mg Vepesid 100mg capsules | 10 capsule [PoM] £87.23

Powder for solution for injection

▶ Etopophos (Cheplapharm Arzneimittel GmbH)

Etoposide (as Etoposide phosphate) 100 mg Etopophos 100mg powder for solution for injection vials | 10 vial [PoM] £261.68

ANTINEOPLASTIC DRUGS > TAXANES

Cabazitaxel

11-Feb-2019

● INDICATIONS AND DOSE

Treatment of hormone refractory metastatic prostate cancer in patients who have previously been treated with a docetaxel-containing regimen (in combination with prednisone or prednisolone)

- ▶ BY INTRAVENOUS INFUSION
- ▶ **Adult:** (consult product literature or local protocols)

- **INTERACTIONS** → Appendix 1: taxanes
- **SIDE-EFFECTS**

- ▶ **Common or very common** Acute kidney injury · alopecia · anaemia · anxiety · appetite decreased · arrhythmias · arthralgia · asthenia · chest pain · chills · confusion · conjunctivitis · constipation · cough · cystitis · deep vein thrombosis · dehydration · diarrhoea · dizziness · dry mouth · dyspnoea · excessive tearing · fever · gastrointestinal discomfort · gastrointestinal disorders · haemorrhage · headache · hydropnephrosis · hyperglycaemia · hypersensitivity · hypertension · hypokalaemia · hypotension · increased risk of infection · lethargy ·